English
Arabic
Chinese (Simplified)
Dutch
Esperanto
French
German
Greek
Italian
Japanese
Korean
Portuguese
Russian
Spanish
UrduSocial isolation may negatively impact bone health, suggests a study conducted in mice being presented Sunday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
Tag: endo 2023
Single hospital study finds transgender teenagers rarely choose to discontinue hormone therapy
A three-year-long retrospective cohort study of a single Atlanta hospital’s patient population found transgender and gender-diverse teenagers rarely chose to discontinue gender-affirming hormone therapy, according to a study being presented Sunday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
Prompt testosterone treatment improves mental health of transgender, gender-diverse people
Receiving rapid access to testosterone therapy reduced feelings of gender dysphoria and led to a clinically significant reduction in depression as well as a 50% reduction in suicidality among transgender and gender diverse adults, according to research being presented Sunday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago.
Radioactive iodine or surgery associated with increased survival in hyperthyroidism
Hyperthyroidism treatment like radioactive iodine or surgery was associated with a decreased risk for death, according to research being presented Saturday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago.
Transgender people seen in the ER much more likely than cisgender people to be admitted to hospital
Transgender people who come to the emergency room for care tend to be sicker than cisgender people who are otherwise similar to them and are much more likely to be admitted to the hospital once they visit the ER, according to a study being presented Saturday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
Study finds “robotic pill” can safely deliver injectable osteoporosis drug
A proven and effective medication for osteoporosis, which is currently only available as an injection, can be administered orally using a novel “robotic pill,” according to a study presented Saturday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
Growing number of hypothyroidism patients receiving treatment other than levothyroxine
The use of thyroid hormones other than the commonly prescribed hormone medicine levothyroxine to treat hypothyroidism, or underactive thyroid, is increasing, according to a study being presented Friday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
Endocrine-disrupting chemicals may raise risk of cognitive disorders in future generations, animal study finds
Adverse cognitive effects linked to polychlorinated biphenyls (PCBs) exposure, a type of endocrine-disrupting chemical (EDC), have the potential to be passed down through generations, according to an animal study being presented Thursday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
Some breast cancer treatments may limit effectiveness of weight loss medications
Breast cancer medications, called aromatase inhibitors, may lessen the effect of weight loss drugs, according to a new study being presented Friday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
CGM alarms often not set to alert children with diabetes to harmful blood glucose fluctuations
Children and teenagers who use continuous glucose monitors (CGM) to manage diabetes often fail to use the appropriate alarm settings to alert to dangerously low or harmful high blood sugar levels, according to a study being presented Thursday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill. This variability makes the monitors less useful in tracking glucose levels.
Statin alternative lowers risk of cardiac events as well as cholesterol levels
A medication called bempedoic acid reduced the risk of cardiac events as well as statins and may offer an alternative to the popular cholesterol-reducing medications, according to industry-supported research being presented Thursday at ENDO 2023, the Endocrine Society’s annual meeting, in Chicago, Ill.
Gestational diabetes cases increased during the COVID-19 pandemic
More pregnant women developed gestational diabetes during the COVID-19 pandemic than in the preceding two years, according to research being presented on Thursday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
Women with polycystic ovary syndrome may face increased risk of death
People with polycystic ovary syndrome (PCOS) have a 47% increased risk for death at a younger age compared with those without the condition, according to research being presented on Sunday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
Full recovery may be possible among men who use steroids for muscle growth
There may be hope for full recovery among men who wish to stop using anabolic-androgenic steroids for muscle growth, according to data being presented on Saturday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
Body image concerns significantly higher in women living with PCOS
Women living with polycystic ovary syndrome (PCOS) experience greater body image concerns than individuals without the condition, according to research being presented Saturday at ENDO 2023, the Endocrine Society’s annual meeting in Chicago, Ill.
ENDO 2023 press conferences to highlight emerging technology and diabetes research
Researchers will delve into the latest research in diabetes, obesity, reproductive health and other aspects of endocrinology during the Endocrine Society’s ENDO 2023 news conferences June 15-18.